|
1
|
Yao JC, Eisner MP, Leary C, Dagohoy C,
Phan A, Rashid A, Hassan M and Evans DB: Population-based study of
islet cell carcinoma. Ann Surg Oncol. 14:3492–3500. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ito T, Sasano H, Tanaka M, Osamura RY,
Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, et al:
Epidemiological study of gastroenteropancreatic neuroendocrine
tumors in Japan. J Gastroenterol. 45:234–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klimstra DS, Arnold R, Capella C, et al:
Neuroendocrine neoplasms of the pancreasWHO classification of
tumours of the digestive system. Bosman FT, Carneiro F, Hruban RH
and Theise ND: IARC Press; Lyon: pp. 322–326. 2010
|
|
4
|
Eldor R, Glaser B, Fraenkel M, Doviner V,
Salmon A and Gross DJ: Glucagonoma and the glucagonoma
syndrome-cumulative experience with an elusive endocrine tumour.
Clin Endocrinol (Oxf). 74:593–598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wermers RA, Fatourechi V, Wynne AG, Kvols
LK and Lloyd RV: The glucagonoma syndrome. Clinical and pathologic
features in 21 patients. Medicine (Baltimore). 75:53–63. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soga J and Yakuwa Y:
Glucagonomas/diabetico-dermatogenic syndrome (DDS): A statistical
evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg.
5:312–319. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anne Couvelard and Olivia Hentic:
GlucagonomaPancreatic Neuroendocrine Neoplasms: Practical Approach
to Diagnosis, Classification, and Therapy. Stefano LR and Fausto S:
Springer International Publishing; Switzerland: pp. 81–87. 2015
|
|
8
|
Becker SW, Kahn D and Rothman S: Cutaneous
manifestations of internal malignant tumors. Arch Dermatol
Syphilol. 45:1069–1080. 1942. View Article : Google Scholar
|
|
9
|
McGavran MH, Unger RH, Recant L, Polk HC,
Kilo C and Levin ME: A glucagon-secreting alpha-cell carcinoma of
the pancreas. N Engl J Med. 274:1408–1413. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wilkinson DS: Necrolytic migratory
erythema with pancreatic carcinoma. Proc R Soc Med. 64:pp.
1197–1198. 1971; PubMed/NCBI
|
|
11
|
Kindmark H, Sundin A, Granberg D, Dunder
K, Skogseid B, Janson ET, Welin S, Oberg K and Eriksson B:
Endocrine pancreatic tumors with glucagon hypersecretion: A
retrospective study of 23 cases during 20 years. Med Oncol.
24:330–337. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
PubMed [Internet]. Bethesda (MD): National
Library of Medicine (US). [1946]. 2016 January 23https://www.ncbi.nlm.nih.gov/pubmed/
|
|
13
|
Papotti M, Bongiovanni M, Volante M, Allìa
E, Landolfi S, Helboe L, Schindler M, Cole SL and Bussolati G:
Expression of somatostatin receptor types 1–5 in 81 cases of
gastrointestinal and pancreatic endocrine tumors. A correlative
immunohistochemical and reverse-transcriptase polymerase chain
reaction analysis. Virchows Arch. 440:461–475. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lepage C, Rachet B and Coleman MP:
Survival from malignant digestive endocrine tumors in England and
Wales: A population-based study. Gastroenterology. 132:899–904.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McGevna L and Tavakkol Z: Images in
clinical medicine. Necrolytic migratory erythema. N Engl J Med.
362:e12010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McGevna L, McFadden D, Ritvo J and
Rabinowitz T: Glucagonoma-associated neuropsychiatric and affective
symptoms: Diagnostic dilemmas raised by paraneoplastic phenomena.
Psychosomatics. 50:548–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Remes-Troche JM, Garcia-de-Acevedo B,
Zuñiga-Varga J, Avila-Funes A and Orozco-Topete R: Necrolytic
migratory erythema: A cutaneous clue to glucagonoma syndrome. J Eur
Acad Dermatol Venereol. 18:591–595. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pujol RM, Wang CY, el-Azhary RA, Su WP,
Gibson LE and Schroeter AL: Necrolytic migratory erythema:
Clinicopathologic study of 13 cases. Int J Dermatol. 43:12–18.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson DS, Coel MN and Bornemann M:
Current imaging and possible therapeutic management of glucagonoma
tumors: A case report. Clin Nucl Med. 25:120–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Halvorson SA, Gilbert E, Hopkins RS, Liu
H, Lopez C, Chu M, Martin M and Sheppard B: Putting the pieces
together: Necrolytic migratory erythema and the glucagonoma
syndrome. J Gen Intern Med. 28:1525–1529. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alkemade JA, van Tongeren JH, van Haelst
UJ, Smals A, Steijlen PM and van de Kerkhof PC: Delayed diagnosis
of glucagonoma syndrome. Clin Exp Dermatol. 24:455–457. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kimbara S, Fujiwara Y, Toyoda M, Chayahara
N, Imamura Y, Kiyota N, Mukohara T, Fukunaga A, Oka M, Nishigori C
and Minami H: Rapid improvement of glucagonoma-related necrolytic
migratory erythema with octreotide. Clin J Gastroenterol.
7:255–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang-Chretien K, Chew JT and Judge DP:
Reversible dilated cardiomyopathy associated with glucagonoma.
Heart. 90:e442004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Demir OM, Paschou SA, Ellis HC,
Fitzpatrick M, Kalogeropoulos AS, Davies A, Thompson J, Davies SW
and Grapsa J: Reversal of dilated cardiomyopathy after glucagonoma
excision. Hormones (Athens). 14:172–173. 2015.PubMed/NCBI
|
|
25
|
Gaiser CA and Dhawan N: Paradoxical
presentation of glucagonoma with delayed onset of necrolytic
migratory erythema. Am J Med. 128:e1–e2. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beattie PE, Fleming CJ, Evans AT, Sheppard
DG, Leese GP, Dow E and Tait IS: Glucagonoma syndrome presenting as
psoriasis. QJM. 95:834–835. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shyr YM, Su CH, Lee CH, Wu CW and Lui WY:
Glucagonoma syndrome: A case report. Zhonghua Yi Xue Za Zhi
(Taipei). 62:639–643. 1999.PubMed/NCBI
|
|
28
|
Nightingale KJ, Davies MG and Kingsnorth
AN: Glucagonoma syndrome: Survival 24 years following diagnosis.
Dig Surg. 16:68–71. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Recant L, Perrino PV, Bhathena SJ,
Danforth DN Jr and Lavine RL: Plasma immunoreactive glucagon
fractions in four cases of glucagonoma: Increased ‘large
glucagon-immunoreactivity’. Diabetologia. 12:319–326. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kitamura Y, Sato M, Hatamochi A and
Yamazaki S: Necrolytic migratory erythema without glucagonoma
associated with hepatitis B. Eur J Dermatol. 15:49–51.
2005.PubMed/NCBI
|
|
31
|
Technau K, Renkl A, Norgauer J and Ziemer
M: Necrolytic migratory erythema with myelodysplastic syndrome
without glucagonoma. Eur J Dermatol. 15:110–112. 2005.PubMed/NCBI
|
|
32
|
Yamashita S, Tanaka N, Takahashi M, Nagai
M, Furuya T, Suzuki Y and Nomura Y: Pancreatic insulinoma combined
with glucagon positive cell: A case report. World J Gastrointest
Surg. 5:68–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lolis MS, Krishtul A, Vidal C, Shim-Chang
H, Phelps R and Lebwohl M: Necrolytic migratory erythema associated
with a metastatic neuroendocrine tumor. Cutis. 87:78–80.
2011.PubMed/NCBI
|
|
34
|
Adams DR, Miller JJ and Seraphin KE:
Glucagonoma syndrome. J Am Acad Dermatol. 53:690–691. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schwartz RA: Glucagonoma and
pseudoglucagonoma syndromes. Int J Dermatol. 36:81–89. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Miller HC, Kidd M, Modlin IM, Cohen P,
Dina R, Drymousis P, Vlavianos P, Klöppel G and Frilling A:
Glucagon receptor gene mutations with hyperglucagonemia but without
the glucagonoma syndrome. World J Gastrointest Surg. 7:60–66. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Glueck CJ, Phillips HG, Cameron D and Wang
P: Estrogen replacement in a protein S deficient patient leads to
diarrhea, hyperglucagonemia, and osteonecrosis. JOP. 2:323–329.
2001.PubMed/NCBI
|
|
38
|
Vanderlan WB, Zhang Z and Abouljoud MS:
Duodenal enteroglucagonoma revealed by differential comparison of
serum and tissue glucagon reactivity with Siemens' Double Glucagon
Antibody and DakoCytomation's Polyclonal Rabbit Anti-Human
Glucagon: A case report. J Med Case Rep. 4:1782010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Plöckinger U, Rindi G, Arnold R, Eriksson
B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC,
et al: Guidelines for the diagnosis and treatment of neuroendocrine
gastrointestinal tumours. A consensus statement on behalf of the
European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology.
80:394–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Melen-Mucha G, Lawnicka H,
Kierszniewska-Stepien D, Komorowski J and Stepien H: The place of
somatostatin analogs in the diagnosis and treatment of the
neuoroendocrine glands tumors. Recent Pat Anticancer Drug Discov.
1:237–254. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fernández-Cruz L, Blanco L, Cosa R and
Rendón H: Is laparoscopic resection adequate in patients with
neuroendocrine pancreatic tumors? World J Surg. 32:904–917. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sarmiento JM, Que FG, Grant CS, Thompson
GB, Farnell MB and Nagorney DM: Concurrent resections of pancreatic
islet cell cancers with synchronous hepatic metastases: Outcomes of
an aggressive approach. Surgery. 132:976–983. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kindmark H, Sundin A, Granberg D, Dunder
K, Skogseid B, Janson ET, Welin S, Oberg K and Eriksson B:
Endocrine pancreatic tumors with glucagon hypersecretion: A
retrospective study of 23 cases during 20 years. Med Oncol.
24:330–337. 2007. View Article : Google Scholar : PubMed/NCBI
|
